Abstract 130P
Background
In carcinoma esophagus patients where large volumes of lymphocyte producing organs and organs with circulating lymphocytes are exposed to radiation field, Radiation induced lymphopenia (RIL) is quite profound. Absolute Lymphocyte Count (ALC) has been postulated to have a crucial impact on treatment outcomes.In this study, dosimetric analysis on the organs at risk (OARs) for lymphopenia and its effect on pathological complete response (PCR) was assessed.
Methods
Carcinoma Esophagus patients who underwent neoadjuvant chemo-radiotherapy(NACT-RT) and definitive surgery from December 2018 to March 2021 were studied retrospectively. Data collected included baseline and weekly ALC, PCR on histopathology, mean dose (Dmean) and volume based dosimetry of the OARs for lymphopenia (thoracic vertebrae, bilateral lungs, liver, heart and spleen) and the effective dose to the circulating lymphocytes (EDIC), calculated using the formulae 0.12 (Dmean lung) + 0.08 (Dmean heart) + [0.45+ 0.35x 0.85(no of fractions/45ˆ1/2] Dmean body. PCR rates were correlated with ALC using Spearman’s correlation. Dosimetric parameters and EDIC was correlated with ALC using Pearson’s correlation test (p value<0.05).
Results
33 patient’s data who were eligible for the study was analysed. On Pearson’s correlation test the thoracic vertebrae Dmean (p-0.008) and V15 (p-0.012), liver Dmean (p-0.034) and V20 (p-0.038), heart Dmean (p-0.013) and V15 (p-0.022), spleen Dmean (p-0.040) were found to have significant correlation with ALC nadir. The mean EDIC was 6.21 (SD±5). No significant correlation between EDIC and ALC nadir was identified. 5% of patients did not achieve PCR at surgery. Spearman’s correlation test did not show a significant correlation between PCR and ALC nadir.
Conclusions
RIL has been demonstrated to have a negative impact on treatment outcomes. In our study, we discovered that dosimetric parameters of Dmean and volume based analysis of the OARs for lymphopenia were strongly correlated with ALC Nadir. Statistically significant correlation between ALC nadir and PCR rates was not seen. A larger multicentric study with a large number of patients, however, may be required to statistically prove our hypothesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
118P - Association between stomach cancer with behavioral and dietary factors: A case control study from Nepal
Presenter: Arun Shahi
Session: Poster viewing 02
119P - Clinicopathological features and roles of lymph node metastases in gastric cancer: A single-center retrospective study in China
Presenter: yuming zhang
Session: Poster viewing 02
120P - Clinical implication of DNA damage response gene in advanced gastric cancer stage IV and recurrent gastric cancer patients after gastrectomy treated palliative chemotherapy
Presenter: In Gyu Hwang
Session: Poster viewing 02
121P - Treatment patterns and outcomes of recurrent/metastatic esophageal cancer: Real-world data
Presenter: Amrith B P
Session: Poster viewing 02
122P - Efficacy and safety of mFOLFOX-6 in advanced gastric cancer: A prospective observational study
Presenter: Amrith B P
Session: Poster viewing 02
123P - Sarcomatoid carcinoma of gall bladder: A series of 14 cases from a single tertiary-care oncology centre
Presenter: Subhash Yadav
Session: Poster viewing 02
124P - Clinical profile and treatment outcomes of hepatocellular carcinoma from a tertiary care hospital in South India: A retrospective study
Presenter: Gayathri Nair
Session: Poster viewing 02
125P - A parametric network meta-analysis of PD-1 inhibitors in second-line treatment for advanced esophageal squamous cell carcinoma
Presenter: Shubhram Pandey
Session: Poster viewing 02
126P - Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study
Presenter: Keitaro Shimozaki
Session: Poster viewing 02
127P - LABS score: The prognostic tool for advanced hepatocellular carcinoma treated with FOLFOX4 and real-world efficacy from a single-center retrospective study
Presenter: Jirapat Wonglhow
Session: Poster viewing 02